This analysis demonstrates the importance of performing subtype-specific analyses in breast cancer, as breast cancer is an extremely heterogeneous disease and prognostic pathways in ER−/HER2− and HER2+ breast cancer subtypes are far more similar to prognostic pathways in ovarian cancer than with prognostic pathways in ER+ breast cancer subtypes. The gene discussed is ERBB2; the disease is breast cancer.